Remove Competition Remove Pharmaceutical manufacturing Remove White Paper
article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

Investing in areas that have demonstrated a good track record of success for similar companies is a simple way to reduce risk, but in 2022, companies should be careful of investing in overly populated life sciences clusters, which might be too competitive. Download the white paper ‘Charleston, USA: A life sciences hub’ here.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing. 199‒208.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

In December 2022, the US passed its ‘ominous spending bill’ directing the US Food and Drug Administration (US FDA) to establish an advanced manufacturing Centre for excellence and an advanced manufacturing technologies designation programme. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.

article thumbnail

Mitigating the risks of cross-contamination during Oral Solid Dose (OSD) manufacturing

Pharmaceutical Technology

Tablet manufacturing, which is the most common OSD form, takes an API dry powder ingredient and compresses it to form tablets, which can be coated or uncoated. Compared to other dosage forms, tablets are simpler to manufacture, package, and transport.

article thumbnail

What a mild recession could mean for small biotechs in 2023

Pharmaceutical Technology

To build an advanced pharmaceutical manufacturing cluster in the Richmond-Petersburg area, the Alliance for Building Better Medicine aims to support the early growth of local pharmaceutical manufacturers. The US Department of Commerce’s Economic Development Administration (EDA) awarded the organization $52.9

article thumbnail

Using big data to stabilise pharma supply chains in an age of disruption

Pharmaceutical Technology

In an age of disruption, technology is key to enabling pharmaceutical manufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised.

Pharma 52